Next Science Ltd - Asset Resilience Ratio
Next Science Ltd (NXS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Next Science Ltd's Asset Resilience Ratio has changed over time. Check NXS strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Next Science Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Next Science Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Next Science Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Next Science Ltd Industry Peers by Asset Resilience Ratio
Compare Next Science Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Next Science Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Next Science Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.21 Million ≈ $6.52 Million |
-- |
| 2023-12-31 | 0.21% | AU$37.82K ≈ $26.76K |
AU$17.90 Million ≈ $12.67 Million |
+0.01pp |
| 2022-12-31 | 0.21% | AU$37.79K ≈ $26.74K |
AU$18.37 Million ≈ $13.00 Million |
-2.47pp |
| 2021-12-31 | 2.68% | AU$366.00K ≈ $258.97K |
AU$13.67 Million ≈ $9.68 Million |
-28.14pp |
| 2020-12-31 | 30.81% | AU$7.24 Million ≈ $5.12 Million |
AU$23.49 Million ≈ $16.62 Million |
-14.88pp |
| 2019-12-31 | 45.70% | AU$10.38 Million ≈ $7.34 Million |
AU$22.71 Million ≈ $16.07 Million |
-- |
About Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more